XML 32 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2
12. Segments
6 Months Ended
Sep. 30, 2016
Segment Reporting [Abstract]  
Segments

We operate our businesses principally through two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic business activities. Our reportable segments have been determined based on the nature of the potential products being developed. We record discrete financial information for ESI and our chief operating decision maker reviews ESI’s operating results in order to make decisions about resources to be allocated to the ESI segment and to assess its performance.

 

Aethlon’s revenue is generated primarily from government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead to the ESI segment.

 

The following tables set forth certain information regarding our segments:

 

   Six Months Ended September 30, 
   2016   2015 
Revenues:        
Aethlon  $392,073   $380,874 
ESI        
Total Revenues  $392,073   $380,874 
           
Operating Losses:          
Aethlon  $(3,281,530)  $(1,911,219)
ESI   (76,999)   (303,113)
Total Operating Loss  $(3,358,529)  $(2,214,332)
           
Net Losses:          
Aethlon  $(4,323,003)  $(2,165,152)
ESI   (76,999)   (303,113)
Net Loss Before Non-Controlling Interests  $(4,400,002)  $(2,468,265)
           
Cash:          
Aethlon  $553,884   $4,208,554 
ESI   2,468    802 
Total Cash  $556,352   $4,209,356 
           
Total Assets:          
Aethlon  $914,179   $4,677,989 
ESI   36,656    27,486 
Total Assets  $950,835   $4,705,475 
           
Capital Expenditures:          
Aethlon  $2,961   $ 
ESI        
Capital Expenditures  $2,961   $ 
           
Depreciation and Amortization:          
Aethlon  $10,822   $8,886 
ESI   9,790    9,790 
Total Depreciation and Amortization  $20,612   $18,676 
           
Interest Expense:          
Aethlon  $(78,743)  $(253,933)
ESI        
Total Interest Expense  $(78,743)  $(253,933)